Approximately 1% of all AIDS cases are haemophiliacs. LAV/HTLV-III is transmitted by blood and in factor VIII concentrates. Since 1981, increasing numbers of haemophiliacs have been infected, as indicated by detection of antibodies to LAV/HTLV-III. Up to 90% of haemophiliacs in some populations are now seropositive, but to date less than 1% have progressed to clinical AIDS. Immunological abnormalities, in particular reduced T-lymphocyte helper/suppressor ratios, are common in haemophiliacs treated with factor VIII. Such abnormalities do not necessarily indicate past infection by the AIDS virus, but they may predispose to infection following exposure to the virus. Blood Transfusion agencies are introducing screening tests for antibodies to LAV/HTLV-III to help prevent the spread of AIDS by blood products. Heat treated factor VIII concentrate is now available and appears not to transmit AIDS. Factor IX concentrate may also transmit LAV/HTLV-III, but less frequently. A few cases of AIDS have occurred in Haemophilia B (Christmas Disease) patients.
所有艾滋病病例中约1%是血友病患者。淋巴腺病相关病毒/人嗜T淋巴细胞病毒III型通过血液及VIII因子浓缩剂传播。自1981年以来,如通过检测针对淋巴腺病相关病毒/人嗜T淋巴细胞病毒III型的抗体所示,受感染的血友病患者数量不断增加。在一些人群中,高达90%的血友病患者现在血清呈阳性,但迄今为止只有不到1%发展为临床艾滋病。在用VIII因子治疗的血友病患者中,免疫异常,特别是T淋巴细胞辅助/抑制比例降低很常见。此类异常不一定表明过去感染了艾滋病病毒,但可能使他们在接触该病毒后更易受到感染。输血机构正在引入针对淋巴腺病相关病毒/人嗜T淋巴细胞病毒III型抗体的筛查测试,以帮助预防艾滋病通过血液制品传播。现在有经过热处理的VIII因子浓缩剂,似乎不会传播艾滋病。IX因子浓缩剂也可能传播淋巴腺病相关病毒/人嗜T淋巴细胞病毒III型,但频率较低。乙型血友病(克里斯马斯病)患者中出现了一些艾滋病病例。